Hutchinson Technology (HTCH) shares are up close to 16% to about $4.28 in mid-day trading Monday. Not seeing any news to account for the move. Approximately 930K shares have already changed hands, compared to the stock’s average daily volume of 280,757 shares.
During today’s trading session, HTCH gapped open sharply higher and climbed for the majority of the morning, before settling into an intraday range of $4.17 to $4.25 with its 52-week range being $1.96 to $4.85.
Fundamentally, HTCH shows the following financial data:
· $261 million cash, $142.47 million total debt
· $119,070 million total current assets
· $23.90 million trailing-12 gross profit
· $261 million revenue
On valuation measures, Hutchinson Technology shares have a t-12 price/sales ratio of 0.40, and a price/book for the same period of 1.09. EPS is ($1.44). HTCH has a market cap of $118.12 million and a median Wall Street price target of $4.95.
Shares of Hutchinson, Minnesota-based company are up more than 5.71% year-over-year, and 5.71% year-to-date.
Alexza Pharmaceuticals Inc. (ALXA) is trading at unusually high volume Monday with 846K shares changing hands. It is currently at 6x its average daily volume and trading up 15.74% at $2.50. Not seeing any news or rumors to account for the move.
Alexza Pharmaceuticals is a Mountain View, Calif.-based firm that focuses on the development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its stock has a price/sales ratio of 7.74 with a 52-week trading range of $1.25 to $5.93. The T-12 operating margin at Alexza is (730.23%). ALXA‘s revenue for the same period is $5.42 million.
Alexza Pharmaceuticals has market cap of $49 million.
Shares of Second Sight Medical Products, Inc. (EYES) are higher by 9.70% in midday trading on Monday, as the stock continues to see gains following the company’s announcement that Health Canada has approved the Argus II Retinal Prosthesis System for treatment of individuals with severe to profound outer retinal degeneration. SSMP said Argus II is the first approved ‘bionic eye’ in Canada for the treatment of blindness due to outer retinal degeneration.
“This is one of the most exciting medical developments I have witnessed in my career,” said in a statement Robert Devenyi, MD, FACS, Ophthalmologist-in-Chief, Donald K. Johnson Eye Centre and Director, Retinal Services, at the University Health Network. “The Argus II offers so much hope and possibility for patients with degenerative eye disease.”
EYES shares recently gained $1.16 to $12.00. The stock is down 39% year-over-year ; up 16.96% year-to-date. In the past 52 weeks, shares of Sylmar, Calif.-based company have traded between a low of $10.00 and a high of $24.02.
Second Sight Medical Products closed Friday at $10.84. The name has a total market cap of $415.50M.
SanDisk Corp. (SNDK) shares declined nearly 14% to $83.76 in midday trading Monday after the company lowered Q4 revenue guidance. SanDisk said it now estimates its total revs to be $1.73 billion, lower than the previously forecasted revenue range of $1.80 billion to $1.85 billion.
On valuation measures, SanDisk Corp., currently valued at $18.42B, has a median Wall Street price target of $110.00 with a high target of $135.00. Approximately 17M shares have already changed hands, compared to the stock’s average daily volume of 3.26M.
In the past 52 weeks, shares of SNDK have traded between a low of $66.80 and a high of $108.77 with the 50-day MA and 200-day MA located at $100.45 and $96.93 levels, respectively. Additionally, shares of SNDK trade have a Relative Strength Index (RSI) and MACD indicator of 27.46 and -4.97, respectively.
SNDK currently prints a one year return of about 35.23%, and a year-to-date loss of less than one percent.
Leave a Reply